Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan

Akihiko Morita, Satoshi Kamei, Masayuki Minami, Kazuto Yoshida, Satoshi Kawabata, Hiroshi Kuroda, Yasushi Suzuki, Nobuo Araki, Yasuo Iwasaki, Rei Kobayashi, Naoki Hayashi, Tetsuyuki Hirayama, Jun Ochiai, Miki Ueda, Yuka Yamagishi, Jun Ichi Niwa, Katsuro Shindo, Yoshihisa Fukushima, Tomohiro Takita, Takayuki SatoShigeru Sato, Hiroshige Mikamo, Satoshi Iwata

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35-71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 μg/ml up to 8.47 h and was over 1 μg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens.

Original languageEnglish
Pages (from-to)535-540
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume20
Issue number9
DOIs
Publication statusPublished - 2014 Sep

Keywords

  • Adult
  • Bacterial meningitis
  • Efficacy
  • Japanese
  • Meropenem
  • Safety

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan'. Together they form a unique fingerprint.

  • Cite this

    Morita, A., Kamei, S., Minami, M., Yoshida, K., Kawabata, S., Kuroda, H., Suzuki, Y., Araki, N., Iwasaki, Y., Kobayashi, R., Hayashi, N., Hirayama, T., Ochiai, J., Ueda, M., Yamagishi, Y., Niwa, J. I., Shindo, K., Fukushima, Y., Takita, T., ... Iwata, S. (2014). Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. Journal of Infection and Chemotherapy, 20(9), 535-540. https://doi.org/10.1016/j.jiac.2014.04.013